• No results found

Mechanistic studies on long peptide based vaccins for the use in cancer therapy. Bijker, M.S.

N/A
N/A
Protected

Academic year: 2021

Share "Mechanistic studies on long peptide based vaccins for the use in cancer therapy. Bijker, M.S."

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Mechanistic studies on long peptide based vaccins

for the use in cancer therapy.

Bijker, M.S.

Citation

Bijker, M. S. (2007, November 1). Mechanistic studies on long peptide based vaccins for the use in cancer therapy. Retrieved from https://hdl.handle.net/1887/12430

Version: Corrected Publisher’s Version License:

Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/12430

Note: To cite this publication please use the final published version (if applicable).

(2)

Stellingen

The lack of long-lived effector CD8+ T cells in cancer patients after minimal CTL peptide vaccination can be explained by the fact that such vaccine induces CD8+ T cell tolerance (this thesis, chapter 2).

Increased duration of Ag presentation enhances the magnitude of the CD8+ T cell response, however too long Ag presentation can be detrimental for the CD8+ T cell (this thesis, chapter 2&3).

Understanding the pharmacokinetics of peptide-based vaccines is essential for further optimization of these vaccines (this thesis, chapter 3).

The level of tetramer+ CD8+ T cells after in vitro stimulation is not indicative of the vaccine’s therapeutic anti-tumor potential (this thesis, chapter 3 & 4).

Enhanced antigen uptake by dendritic cells after vaccination with a Toll-Like Receptor adjuvant conjugated to a long peptide, is mediated by a different receptor than the cognate Toll-Like Receptor (this thesis, chapter 5).

Vaccine induced T cells in which cbl-b is (temporarily) inhibited, has great potential for future cancer therapy (this thesis, chapter 6).

Long synthetic peptide vaccines have once been considered as “short synthetic peptide”

vaccines (Townsend et al., Cell 1986;44(6):959-68 & Gao et al., 1991;147(10):3268-73).

Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance (Den Boer et al., J. Immunology 2001;

167(5):2522-8).

The Y1 receptor for Neuropeptide Y: a key modulator of the adaptive immune system (Wheway et al., 2007;28(2):453-8).

The purpose of life is much larger than what the practice of science can achieve (V. K.) Facts do not cease to exist because they are ignored (Aldous Huxley).

The number one rule of science is to have fun.

Nothing in life is to be feared. It is only to be understood (Marie Curie).

Referenties

GERELATEERDE DOCUMENTEN

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded

Synthesis and evaluation of peptide and nucleic acid based Toll-like receptor ligands..

Therefore to evaluate the relevance of TLR expression for the enhanced uptake, bone-marrow dendritic cells BMDCs purified from wild-type WT, TLR2-/-, and TLR9-/- mice were

Similarly, it has been shown that the vaccination induced anti-TC-1 tumor response depends on CD4 + T cell help (22). S2) followed by TC-1 inoculation. As expected, depletion of CD4

These two factors – the predominant local presentation of peptides and the provision of CD4 + T-cell help (53,75)- which are lacking in most of the peptide vaccines used in

Wanneer een peptide van 30 aminozuren lang wordt gebruikt voor vaccinatie - waar dezelfde sequentie van 8-10 aminozuren in zit - blijkt de CD8+ T cel respons veel sterker te zijn

De mensen van het proefdierhuis wil ik bedanken voor alle hulp bij het doen van mijn experimenten.. Wouter, bedankt voor het maken van de mooie voorkant van